Is SUTRO BIOPHARMA, INC. (STRO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.6% / 30% | 76.5% / 30% | 2.1% / 30% | 71.6% / 5% | ✗ NOT HALAL |
| DJIM | 5.6% / 33% | 76.5% / 33% | 2.1% / 33% | 71.6% / 5% | ✗ NOT HALAL |
| MSCI | 6.0% / 33% | 81.8% / 33% | 2.2% / 33% | 71.6% / 5% | ✗ NOT HALAL |
| S&P | 5.6% / 33% | 76.5% / 33% | 2.1% / 33% | 71.6% / 5% | ✗ NOT HALAL |
| FTSE | 6.0% / 33% | 81.8% / 33% | 2.2% / 50% | 71.6% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -62.4% | |
| Operating Margin | -289.0% | |
| Net Margin | -186.5% | |
| Return on Assets (ROA) | -23.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$192M |
| Free Cash Flow | -$195M |
| Total Debt | $23M |
| Current Ratio | 2.0 |
| Total Assets | $387M |
Price & Trading
| Last Close | $24.91 |
| 50-Day MA | $18.99 |
| 200-Day MA | $11.55 |
| Avg Volume | 144K |
| Beta | 1.5 |
|
52-Week Range
$5.20
| |
About SUTRO BIOPHARMA, INC. (STRO)
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SUTRO BIOPHARMA, INC. (STRO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SUTRO BIOPHARMA, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SUTRO BIOPHARMA, INC.'s debt ratio?
SUTRO BIOPHARMA, INC.'s debt ratio is 5.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.0%.
What are SUTRO BIOPHARMA, INC.'s key financial metrics?
SUTRO BIOPHARMA, INC. has a market capitalization of $405M, and revenue of $62M. The company maintains a gross margin of -62.4% and a net margin of -186.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.